Patents by Inventor Lynette A. Fouser
Lynette A. Fouser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8906375Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: November 22, 2010Date of Patent: December 9, 2014Assignee: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Patent number: 8470993Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 22, 2012Date of Patent: June 25, 2013Assignees: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Publication number: 20130005033Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 22, 2012Publication date: January 3, 2013Applicants: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralf R. Minter
-
Patent number: 8187603Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 29, 2009Date of Patent: May 29, 2012Assignees: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Patent number: 8182817Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: January 29, 2010Date of Patent: May 22, 2012Assignees: Wyeth LLC, Medimmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Publication number: 20110212099Abstract: The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-23Type: ApplicationFiled: March 15, 2011Publication date: September 1, 2011Applicant: Wyeth LLCInventors: Spencer C. LIANG, Lynette A. Fouser, Margot O'Toole
-
Publication number: 20110091478Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: November 22, 2010Publication date: April 21, 2011Applicant: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Patent number: 7901684Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: February 20, 2007Date of Patent: March 8, 2011Assignees: Wyeth LLC, Medimmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Patent number: 7811567Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: February 20, 2007Date of Patent: October 12, 2010Assignee: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Publication number: 20100184960Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: January 29, 2010Publication date: July 22, 2010Applicants: Wyeth, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Publication number: 20100015162Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 29, 2009Publication date: January 21, 2010Applicant: WyethInventors: Lynette A. FOUSER, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole